U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H33NO4
Molecular Weight 435.5552
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PAXILLINE

SMILES

CC(C)(O)[C@H]1O[C@H]2CC[C@]3(C)[C@]4(C)[C@H](CC5=C4NC6=C5C=CC=C6)CC[C@@]3(O)C2=CC1=O

InChI

InChIKey=ACNHBCIZLNNLRS-UBGQALKQSA-N
InChI=1S/C27H33NO4/c1-24(2,30)23-20(29)14-18-21(32-23)10-11-25(3)26(4)15(9-12-27(18,25)31)13-17-16-7-5-6-8-19(16)28-22(17)26/h5-8,14-15,21,23,28,30-31H,9-13H2,1-4H3/t15-,21-,23-,25+,26+,27+/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H33NO4
Molecular Weight 435.5552
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Paxilline is a toxic, tremorgenic indole alkaloid produced by Penicillium paxilli. Paxilline is inhibitor of BK channels, and is widely used as a tool compound to test role of BK channels in various conditions. Paxilline demonstrated therapeutic benefit in preclinical model of acute pancreatitis, and was able to induce apoptosis of glioma cell lines in vitro.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
50.0 nM [IC50]
6.7 µM [Ki]
5.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
In the model of acute pancreatitis, under pentobarbital anesthesia (50 mg/kg body weight), a laparotomy was performed and 5% sodium taurocholate (1 ml/kg body weight) was injected into the biliopancreatic duct of the rat in one minute. Then the rat recovered from the anesthesia and was allowed access to water. Paxilline (2.2 μg/kg) was intravenously injected to rats 1 h before or after the injection of sodium taurocholate, respectively. Treatment with paxilline inhibited lockade inhibited the release of inflammatory mediators in rats during acute pancreatitis.
Route of Administration: Intravenous
In Vitro Use Guide
To study inhibition of BK channels, HEK293 cells were transfected with human BK channel alpha-subunit. Whole-cell patch clamp technique was used to study effect of paxilline. The initial membrane potential was 23 mV and characterized by brief hyperpolarizing fluctuations caused by spontaneous channel openings. Application of 1uM paxilline depoarized the cell to -5mV and completely blocked the BK current. The effect of th~ BK-channel blocker paxilline on activation curves was studied in the presence of 0.5 and 30 uM Ca2+. At 30 uM internal Ca2+the maximal current amplitudes in the presence of 30 and 100 nM mixilline were decreased relative to the control experiment. The IC50 value of paxilline was estimated at 50 nM.
Substance Class Chemical
Record UNII
3T9U9Z96L7
Record Status Validated (UNII)
Record Version